P575: GILTERITINIB MAINTENANCE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR FLT3 MUTATED ACUTE MYELOID LEUKEMIA

作者
Andrius Žučenka,Dominika Vasilevska,Guoda Daukėlaitė,Igoris Trociukas,Valdas Pečeliūnas,Regina Pileckytė,Laimonas Griškevičius
出处
期刊:HemaSphere [Wolters Kluwer]
卷期号:7 (S3): e07443aa-e07443aa
标识
DOI:10.1097/01.hs9.0000969204.07443.aa
摘要

Background: Gilteritinib is approved for FLT3 mutated (FLT3m) relapsed or refractory AML (R/R AML). The role of Gilteritinib maintenance for post-allogeneic stem cell transplantation (alloSCT) is under evaluation in multicenter randomized, phase 3 trials. Herein, we present our real-life experience of Gilteritinib maintenance in FLT3m AML patients after alloSCT. Aims: To evaluate the safety and efficacy of Gilteritinib maintenance post alloSCT in FLT3m AML Methods: Data was collected retrospectively. The patients were older than 18 years of age, had undergone alloSCT for FLT3m AML, and started Gilteritinib maintenance post-transplant. All patients provided informed consent for treatment and data collection. We evaluated baseline characteristics, duration and dosing of Gilteritinib maintenance, measurable residual disease (MRD) kinetics, overall survival (OS), and CTCAE v5.0 adverse events of special interest (QT prolongation, ALT/AST elevation, pancreatitis, PRESS syndrome). Results: Eleven patients (6 male) were enrolled in the study. The median age was 64 (46-74) and the median ECOG was 1 (0-2). FLT3-ITD mutation was identified in 8/11 patients, FLT3-TKD in 2/11 and 1 patient had FLT-ITD and FLT3-TKD. All patients had intermediate ELN2022 risk karyotypes. Previous FLT3 inhibitors were used in 10/11 patients (Midostaurin (2), Gilteritinib (5), Midostaurin and Gilteritinib (3). 2/11 patients proceeded to alloSCT in CR1 after standard intensive chemotherapy, whereas 9/11 had R/R AML and were all exposed to Venetoclax+Gilteritinib prior to alloSCT. RIC was administered in 10/11 patients. The median time of starting Gilteritinib after alloSCT was 68 days (28-391) with a median dose of 80mg/d (40-120mg/d). Additional DLIs were used in 2 cases. 8/11 patients were MRD positive prior to Gilteritinib maintenance, whereas 3/11 patients were MRD negative. The median duration of Gilteritinib maintenance was 411 days (19-658). 5/8 patients converted from MRD positive to MRD negative disease on Gilteritinib maintenance. Gilteritinib was stopped in 4 patients due to GVHD (1) or disease relapse (3). All 3 relapsed patients had positive MRD prior to Gilteritinb and had NRAS mutations. Clonal evolution at relapse post-Gilteritinib was identified in 2 cases: loss of FLT3-ITD and acquired monosomal karyotype (1), newly gained BCR-ABL1 translocation (1). PRESS syndrome, pancreatitis, and grade ≥3 QTcF prolongation was not observed. Grade 3 ALT/AST elevation was reported in 2/11 patients. 12 and 24 month OS was 89% and 76%, respectively. Summary/Conclusion: A proportion of FLT3m AML patients remain in prolonged CRs on Gilteritinib maintenance after alloSCT despite prior exposure to Midostaurin, Gilteritinib and Venetoclax. Conversion from positive MRD to negative MRD was confirmed in several cases. Relapses post-Gilteritinib maintenance were enriched with RAS pathway mutations and clinically relevant clonal evolution such as loss of FLT3m or gain of BCR-ABL1. The toxicity of Gilteritinib was manageableKeywords: AML, Allo-SCT, FLT3, Maintenance

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
oosr发布了新的文献求助10
刚刚
刚刚
pp发布了新的文献求助10
刚刚
IceyCNZ发布了新的文献求助10
刚刚
初(*^▽^*)心的应助被哭泣冬瓜采纳,获得10
1秒前
酷波er的应助被檀兮尔采纳,获得10
1秒前
Czz发布了新的文献求助10
1秒前
2秒前
serena发布了新的文献求助20
2秒前
忧心的曼凝的应助被沧海云帆采纳,获得10
2秒前
QQ完成签到,获得积分10
2秒前
2秒前
Brian发布了新的文献求助10
2秒前
nn完成签到,获得积分10
3秒前
科研通AI6.4的应助被Wd采纳,获得10
3秒前
石心粥发布了新的文献求助10
3秒前
4秒前
爆米花的应助被MRCHONG采纳,获得10
4秒前
小马同学发布了新的文献求助10
4秒前
搜集达人的应助被坚定的问芙采纳,获得10
5秒前
年轻雁枫完成签到,获得积分10
5秒前
sun发布了新的文献求助10
5秒前
俊逸博超完成签到,获得积分10
5秒前
hhhhh完成签到,获得积分10
5秒前
周周周发布了新的文献求助10
5秒前
哭泣冬瓜完成签到,获得积分10
6秒前
星辰大海的应助被繁荣的尔风采纳,获得10
6秒前
IceyCNZ完成签到,获得积分10
8秒前
8秒前
科研通AI2S的应助被春天采纳,获得10
9秒前
fancccc完成签到,获得积分10
9秒前
9秒前
1101592875发布了新的文献求助10
10秒前
李健的小迷弟的应助被米饭采纳,获得10
10秒前
11秒前
小马同学完成签到,获得积分10
11秒前
fancccc发布了新的文献求助10
12秒前
小马甲的应助被lsx采纳,获得10
12秒前
NexusExplorer的应助被屹男采纳,获得10
13秒前
李健的小迷弟的应助被vbmc采纳,获得30
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183792
求助须知:如何正确求助?哪些是违规求助? 9573020
关于积分的说明 21828776
捐赠科研通 7780959
什么是DOI,文献DOI怎么找? 3434116
关于科研通互助平台的介绍 2558301
邀请新用户注册赠送积分活动 2480611